WHO Overhauls Blood Cancer Classification System

The Cancer Name Game

In medicine, a name is never just a name. It is a diagnosis, a prognosis, a treatment plan, and sometimes a death sentence. So when the World Health Organization decided to overhaul how it classifies blood cancers, the move was not academic. It was personal for every patient who would receive a new label.

The 5th edition of the WHO Classification of Haematolymphoid Tumours, published in 2022, represents the most radical reorganization of lymphoma and leukemia taxonomy in decades (Alaggio et al., 2022). The authors, led by pathologist Rita Alaggio, did not just add a few new entries to a list. They upended the entire hierarchy. They deleted old entities, renamed others, and introduced concepts that would have seemed alien to a hematologist in 2016.

Why should anyone outside a pathology lab care? Because the way we name a cancer determines how we treat it. And for decades, the system was broken.

The Old System Was a Mess

The previous edition, the revised 4th edition from 2016, was a patchwork. It grouped cancers by where they appeared in the body, by what they looked like under a microscope, and by which proteins they expressed. But these categories often overlapped. A single patient's cancer could fit into multiple boxes. Two pathologists could look at the same biopsy and assign different names.

The problem was not incompetence. It was that the biology of blood cancers is messy. Lymphomas and leukemias arise from cells that are constantly changing, mutating, and differentiating. The old classification tried to impose order by splitting these cancers into ever finer categories. But splitting without understanding the underlying biology created confusion.

Alaggio et al. (2022) describe the new system as "hierarchical." That word sounds dry. But it means something concrete: every cancer is now classified first by the type of cell it came from, then by its genetic features, then by its clinical behavior. The hierarchy runs from biology down to symptoms, not the other way around.

What Changed? Everything.

The New Hierarchy

The old system listed entities in alphabetical order or by anatomical site. The new one uses a tiered structure:

• ▸Cell lineage is the first filter. Is the cancer a B-cell neoplasm, a T-cell neoplasm, or something rarer?
• ▸Maturation stage comes next. Is the cell immature (like a blast) or mature (like a plasma cell)?
• ▸Genetic drivers follow. Does the cancer have a specific mutation or translocation?
• ▸Clinical features are last. Does the patient have localized disease or widespread involvement?

This hierarchy forces pathologists to think like biologists. You cannot just describe what you see. You must trace the cancer back to its origin.

The Deletions

Some entities disappeared entirely. The authors removed "lymphomatoid papulosis" as a separate entity, reclassifying it as a subtype of cutaneous T-cell lymphoma. They deleted "primary effusion lymphoma" as a standalone diagnosis, folding it into the broader category of large B-cell lymphomas associated with HHV-8 infection.

Why remove a diagnosis? Because the old category was misleading. A patient diagnosed with "primary effusion lymphoma" might be treated differently from someone with "large B-cell lymphoma," even though the underlying biology was nearly identical. The deletion forces clinicians to see the connection.

The Renamings

Some names changed to reflect better biology. "Angioimmunoblastic T-cell lymphoma" became "nodal T-follicular helper cell lymphoma, angioimmunoblastic-type." That is a mouthful. But it tells you something the old name did not: this cancer arises from a specific type of helper T cell, not from blood vessels.

"Burkitt lymphoma" lost its association with the word "leukemia" even when it presented in the blood. The authors now call it "Burkitt lymphoma" regardless of where it shows up. This eliminates the confusing distinction between lymphoma and leukemia for a disease that is really one entity.

The New Entities

The authors introduced several new diagnoses. "Breast implant-associated anaplastic large cell lymphoma" is now officially recognized. This is not a theoretical entity. It is a real cancer that develops in a small fraction of women with textured breast implants. Giving it its own category means pathologists will look for it, surgeons will screen for it, and patients will be monitored.

"Pediatric-type follicular lymphoma" was split from adult follicular lymphoma. This matters because children with this cancer have an excellent prognosis and may not need aggressive chemotherapy. The old system lumped them together with adults, leading to overtreatment.

The Methodology: How They Decided

Alaggio et al. (2022) did not conduct a new experiment. They synthesized decades of research. The authors represent a consortium of hematopathologists, geneticists, and clinicians who reviewed thousands of studies, case reports, and clinical trials. They held consensus meetings. They argued. They voted.

The process was not purely democratic. The authors write that decisions were based on "evidence of clinical relevance, biological distinctiveness, and reproducibility of diagnosis." In plain English: a new entity had to matter for treatment, have a unique genetic signature, and be recognizable by different pathologists looking at the same slide.

This third criterion is critical. If two pathologists cannot agree on whether a patient has Entity X or Entity Y, the classification fails. The new system prioritizes diagnoses that are reproducible, even if that means merging some categories that experts once considered separate.

What This Means for Patients

Your Diagnosis May Change

If you were diagnosed with a blood cancer before 2022, your exact label may no longer exist. This is not a mistake. The WHO expects clinicians to reclassify patients using the new system. A patient with "follicular lymphoma, grade 3B" might now be classified as "diffuse large B-cell lymphoma, follicular variant." The treatment may stay the same, but the name carries different prognostic information.

Clinical Trials Will Be Affected

Clinical trials use the WHO classification to define who is eligible. When a category disappears, trials that enrolled patients under the old system must be reinterpreted. A drug that worked for "primary effusion lymphoma" might also work for other HHV-8 associated large B-cell lymphomas, but the trial data cannot prove that directly. Researchers will need to reanalyze their results using the new categories.

Genetic Testing Becomes Mandatory

The new hierarchy places genetic drivers near the top. That means a diagnosis now depends on molecular testing. A pathologist cannot simply look at a biopsy under a microscope and say "this is follicular lymphoma." They need to know if the cells carry the t(14;18) translocation that defines the classic form. If the translocation is absent, the diagnosis may be different.

This shift has practical consequences. Hospitals without access to advanced genetic testing will struggle to apply the new classification. Patients in rural areas or low-income countries may receive less precise diagnoses, not because the pathologists are bad, but because the system demands data they cannot generate.

The Open Questions the Study Does Not Answer

The new classification is a major advance, but it leaves important questions unresolved.

First, how stable are these categories over time? A patient's cancer can evolve. A low-grade lymphoma can transform into an aggressive one. The new system classifies the cancer at the time of biopsy, but it does not tell you how to handle a transformation. Should the patient be reclassified entirely? Or should the original diagnosis persist?

Second, what about rare cancers that do not fit? The authors acknowledge that some entities are defined by a single case report. They included these for completeness, but the evidence base is thin. A pathologist who encounters a tumor that does not match any category must still make a diagnosis. The new system does not solve this problem.

Third, how will the system handle new discoveries? The authors note that the classification will be updated regularly, but they do not specify a process. If a new genetic driver is discovered next year, will it be added immediately? Or will patients wait another five years for the next edition?

Fourth, does the hierarchy actually improve outcomes? The authors assume that classifying by biology will lead to better treatment. But they do not prove this. A randomized trial comparing the old system to the new one is impossible. The evidence is circumstantial: better biology should mean better targeting of therapies. But correlation is not causation.

The Hidden Revolution: Germline Predisposition

One of the most striking changes in the 5th edition is the inclusion of germline predisposition syndromes. For the first time, the WHO recognizes that some blood cancers are hereditary.

The authors list specific syndromes: "Li Fraumeni syndrome, ataxia telangiectasia, Nijmegen breakage syndrome, Bloom syndrome, Fanconi anemia, and constitutional mismatch repair deficiency" (Alaggio et al., 2022). Each of these conditions increases the risk of developing lymphoma or leukemia. But they were previously classified as separate diseases, not as part of the cancer classification itself.

This change has immediate implications. If a patient is diagnosed with a blood cancer and has a family history of similar cancers, the new classification prompts the clinician to consider genetic testing. Finding a germline mutation changes everything. It means the patient's siblings and children may also be at risk. It means the cancer may respond differently to chemotherapy. It means the patient may need different follow up.

The authors are careful to note that these syndromes are "tumor like lesions" rather than full neoplasms. But including them in the classification sends a powerful signal: hereditary risk is part of the cancer story, not a footnote.

The Tumor Like Lesions: What Is Not Cancer

The new classification includes a section on "tumor like lesions" that mimic cancer but are not malignant. These include conditions like "infectious mononucleosis" and "Kikuchi disease." Including them serves a practical purpose: pathologists who encounter these lesions must consider them in the differential diagnosis. A patient with a swollen lymph node might have lymphoma, or they might have a benign reactive condition. The classification forces the pathologist to think about both.

This may seem obvious, but the old system did not list these mimics. Pathologists had to learn them separately. By including them, the WHO reduces the risk of misdiagnosis.

What This Actually Means

• ▸If you are a patient with a blood cancer diagnosis from before 2022, ask your oncologist whether your classification has changed. The new system may affect your prognosis or treatment options. Do not assume your old diagnosis is still accurate.

• ▸If you are a clinician, update your pathology request forms. You need to specify that you want the 5th edition classification. Your pathologist may still be using the old system out of habit. Push for the new one.

• ▸If you are a researcher, reanalyze your clinical trial data using the new categories. The old categories may have masked signals. A drug that failed in a broad category might work in a newly defined subtype.

• ▸If you are a hospital administrator, invest in genetic testing capacity. The new classification cannot be applied without molecular data. Pathologists need access to sequencing, FISH, and immunohistochemistry panels. Without these tools, your institution will fall behind.

• ▸If you are a medical student, learn the hierarchy. The old system of memorizing lists is obsolete. The new system demands that you understand cell lineage, maturation, and genetics. Study the biology, not the names.